Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Capriotti

Psychiatry Lisle, IL Medical Doctor

NPI 1609859271 CMS profile 27077

3033 Ogden Ave, Ste. 210, Lisle, IL 60532

Open in the dashboard

General payments

$2,617

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Capriotti of Lisle, IL is reported in the CMS Open Payments database as having received $2,617 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $499 23
2024 General $554 23
2023 General $552 22
2022 General $321 14
2021 General $13 1
2020 General $37 3
2019 General $643 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Capriotti
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Paul Capriotti were reported at $499. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Paul Capriotti Psychiatry median Middle half National median
2019 $643 $184 $59–$605 $163
2020 $37 $119 $36–$372 $114
2021 $13 $143 $43–$576 $132
2022 $321 $153 $50–$590 $149
2023 $552 $170 $56–$651 $160
2024 $554 $179 $57–$673 $164
2025 $499 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $389 13 payments
  2. AbbVie, Inc. $315 13 payments
  3. Vanda Pharmaceuticals Inc. $266 10 payments
  4. Otsuka America Pharmaceutical, Inc. $246 13 payments
  5. ITI, Inc. $227 11 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $175 1 payment
  7. Allergan Inc. $167 13 payments
  8. Supernus Pharmaceuticals, Inc. $129 6 payments
  9. Idorsia Pharmaceuticals US Inc $92 4 payments
  10. Corium, Inc. $84 4 payments
  11. Other $527 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,442 122 payments
  2. Consulting Fee $175 1 payment
Products named General payments · program years 2019–2025
  1. INGREZZA $389 13 payments
  2. FANAPT $266 10 payments
  3. VRAYLAR Neuroscience $247 16 payments
  4. REXULTI $246 13 payments
  5. VRAYLAR Neuroscience $235 10 payments
  6. ABILIFY MYCITE $175 1 payment
  7. QELBREE $129 6 payments
  8. CAPLYTA Psychiatry $121 6 payments
  9. CAPLYTA Psychiatry $105 5 payments
  10. QUVIVIQ $92 4 payments
  11. Other $982 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,477

Median for Psychiatry & Neurology: 100

Drug cost

$70,420

Median for Psychiatry & Neurology: $2,986

Branded share of claims

31.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Wellbutrin Xl Bupropion Hcl Brand 13 $29,195
Effexor Xr Venlafaxine Hcl Brand 14 $6,603
Lisdexamfetamine Dimesylate Generic 24 $5,668
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 37 $4,773
Methylphenidate Er (La) Methylphenidate Hcl Brand 15 $2,536
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 87 $2,482
Olanzapine Generic 40 $1,946
Duloxetine Hcl Generic 81 $1,677
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 18 $1,577
Clozapine Generic 13 $1,382

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $181
$181 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $117
$117 — —
VRAYLAR
  • AbbVie, Inc. $67
$67 — —
CAPLYTA
  • ITI, Inc. $57
$57 — —
ARISTADA
  • Alkermes, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record